ADMA Biologics (ADMA) Stock Price, News & Analysis

Company Overview

ADMA Biologics, Inc. is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S. Food and Drug Administration (FDA) in 2012 for patients with primary humoral immunodeficiency, and ASCENIV, a high-titer IGIV approved in 2019 for the treatment of similar conditions with targeted antibody coverage against pathogens such as respiratory syncytial virus (RSV). Both products are manufactured in ADMA’s FDA-licensed biologics facility in Boca Raton, Florida, and distributed across the United States through a network of specialty pharmacy and hospital partners.

Founded in 2008 and completing its initial public offering in 2011, ADMA Biologics has invested in expanding its plasma supply chain and production capacity to support long-term growth. The company sources plasma exclusively from U.S. donations, operating its own collection centers while also collaborating with third-party providers to ensure a consistent supply of raw materials for fractionation and downstream processing.

ADMA Biologics is led by President and Chief Executive Officer Adam Grossman, who brings experience in both commercial operations and regulatory affairs within the biopharmaceutical sector. Under his leadership, the company continues to explore new indications for immunoglobulin therapies and to advance its pipeline of additional plasma-derived products designed to enhance patient access and outcomes.

Key Stats

• Today's Range: $8.18 to $8.54
• 50-Day Range: $7.88 to $16.15
• 52-Week Range: $7.21 to $22.37
• Volume: 2.97 million shs
• Average Volume: 6.95 million shs
• Market Capitalization: $1.91 billion
• P/E Ratio: 12.12
• Dividend Yield: N/A
• Price Target: $19.00
• Consensus Rating: Hold

ADMA Biologics Stock Analysis - MarketRank™

ADMA Biologics scored higher than 91% of companies evaluated by MarketBeat, and ranked 49th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

ADMA Biologics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 2 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

ADMA Biologics has a consensus price target of $19.00, representing about 130.6% upside from its current price of $8.24.

Amount of Analyst Coverage

ADMA Biologics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 25.00%

Earnings Growth

Earnings for ADMA Biologics are expected to grow by 25.00% in the coming year, from $0.84 to $1.05 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ADMA Biologics is 12.12, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.79.

Price to Earnings Ratio vs. Sector

The P/E ratio of ADMA Biologics is 12.12, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.01.

Price to Book Value per Share Ratio

ADMA Biologics has a P/B Ratio of 4.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.03% of the float of ADMA Biologics has been sold short.

Short Interest Ratio / Days to Cover

ADMA Biologics has a short interest ratio ("days to cover") of 3.22, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ADMA Biologics has recently increased by 7.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ADMA Biologics does not currently pay a dividend.

Dividend Growth

ADMA Biologics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: -0.13

News Sentiment

ADMA Biologics has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for ADMA Biologics this week, compared to 6 articles on an average week.

Search Interest

Only 33 people have searched for ADMA on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.

MarketBeat Follows

7 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.

Company Ownership

• Score: 3.7 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of ADMA Biologics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $52,015.00 in company stock, which represents 0.0027% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, ADMA Biologics insiders have bought 32.96% more of their company's stock than they have sold. Specifically, they have bought $209,815.00 in company stock and sold $157,800.00 in company stock.

Percentage Held by Insiders

3.90% of the stock of ADMA Biologics is held by insiders.

Percentage Held by Institutions

75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 5/25/2026
• AGM 2026: 6/02/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADMA
• CIK: 1368514
• Web: www.admabiologics.com
• Phone: (201) 478-5552
• Fax: 201-478-5553
• Employees: 530
• Year Founded: 2004

Price Target and Rating

• Average Price Target for ADMA Biologics: $19.00
• High Price Target: $20.00
• Low Price Target: $18.00
• Potential Upside/Downside: +130.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.68
• Trailing P/E Ratio: 12.12
• Forward P/E Ratio: 9.81
• P/E Growth: N/A
• Net Income: $146.93 million
• Net Margins: 32.43%
• Pretax Margin: 40.47%
• Return on Equity: 39.98%
• Return on Assets: 28.08%

Debt

• Debt-to-Equity Ratio: 0.51
• Current Ratio: 6.95
• Quick Ratio: 3.93

Sales & Book Value

• Annual Sales: $510.17 million
• Price / Sales: 3.74
• Cash Flow: $0.65 per share
• Price / Cash Flow: 12.60
• Book Value: $1.68 per share
• Price / Book: 4.90

Miscellaneous

• Outstanding Shares: 231,770,000
• Free Float: 222,734,000
• Market Cap: $1.91 billion
• Optionable: Optionable
• Beta: 0.83